PLoS ONE (Jul 2008)

Antimalarial therapy selection for quinolone resistance among Escherichia coli in the absence of quinolone exposure, in tropical South America.

  • Ross J Davidson,
  • Ian Davis,
  • Barbara M Willey,
  • Keyro Rizg,
  • Shelly Bolotin,
  • Vanessa Porter,
  • Jane Polsky,
  • Nick Daneman,
  • Allison McGeer,
  • Paul Yang,
  • Dennis Scolnik,
  • Roy Rowsell,
  • Olga Imas,
  • Michael S Silverman

DOI
https://doi.org/10.1371/journal.pone.0002727
Journal volume & issue
Vol. 3, no. 7
p. e2727

Abstract

Read online

BackgroundBacterial resistance to antibiotics is thought to develop only in the presence of antibiotic pressure. Here we show evidence to suggest that fluoroquinolone resistance in Escherichia coli has developed in the absence of fluoroquinolone use.MethodsOver 4 years, outreach clinic attendees in one moderately remote and five very remote villages in rural Guyana were surveyed for the presence of rectal carriage of ciprofloxacin-resistant gram-negative bacilli (GNB). Drinking water was tested for the presence of resistant GNB by culture, and the presence of antibacterial agents and chloroquine by HPLC. The development of ciprofloxacin resistance in E. coli was examined after serial exposure to chloroquine. Patient and laboratory isolates of E. coli resistant to ciprofloxacin were assessed by PCR-sequencing for quinolone-resistance-determining-region (QRDR) mutations.ResultsIn the very remote villages, 4.8% of patients carried ciprofloxacin-resistant E. coli with QRDR mutations despite no local availability of quinolones. However, there had been extensive local use of chloroquine, with higher prevalence of resistance seen in the villages shortly after a Plasmodium vivax epidemic (pConclusionsIn these remote communities, the heavy use of chloroquine to treat malaria likely selected for ciprofloxacin resistance in E. coli. This may be an important public health problem in malarious areas.